The abstract is read at the publisher; the summary is JClub's.
CD47 on B16F10 melanoma cells suppresses Fcγ receptor-driven NOX2 reactive oxygen species during ADCP, preventing CD8 T cell engagement and immunotherapeutic responses in wild-type mice.
- Why it matters: Tumor-cell CD47 blocks antibody-dependent phagocytosis, but how this limits adaptive immunity and which phagocyte pathway sets the threshold for tumor control remains unclear.
- What they did: Genome-wide CRISPR screens in macrophages identified NOX2 complex and SIRP as regulators of phagosome acidification; CD47 removal delayed acidification in wild-type but not NOX2-deficient macrophages, and anti-Tyrp1 therapy was tested with CD8/IFNγ/perforin and checkpoint or IL-2 fusion combinations.
- The result: Anti-Tyrp1 cleared CD47-deficient tumors in ~36% of wild-type mice but not NOX2-deficient mice; CD8 T cells and IFN{gamma} were required, and NOX2-deficient mice lacked rechallenge protection despite high initial cure, while MSA-IL-2 supported durable immunity in both genotypes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.